17,261 trials
Hemophilia A With Inhibitor · Hemophilia B With Inhibitor
Primary: Bleeding Episode Prevention Success — 1.4640 score on a scale
Schizophrenia
Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 — -9.7; -17.2 Units on a scale — p=0.001
Breast Cancer
Primary: Pathological Complete Response (pCR) RCB-0 or RCB-1 — 14; 10 Participants — p=<0.01
Glioblastoma · Recurrent Glioblastoma · Brain Tumor
Primary: Efficacy: Median Progression-free Survival (PFS) Rate at 6 Months (PFS-6) — 22.5; 25.0; 18.2 Percentage (%) of subjects
Attenuated Familial Adenomatous Polyposis · Familial Adenomatous Polyposis
Primary: Mean Percent Change in Duodenal Polyp Burden — -29.6 percent change in Duodenal Polyp Burden
Leukemia, Erythroblastic, Acute · Myelodysplastic Syndromes
Primary: Disease Free Survival at 1 Year Post-transplant — 18 Participants
Schizophrenia
Primary: Change From Baseline in the 16-Item Negative Symptoms Assessment (NSA-16) — -2.7; -3.6 units on a scale — p=0.732
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Adult Medulloblastoma · Childhood Medulloblastoma · Neuroblastoma
Primary: Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With Pathology — 28; 0; 1; 5 Participants
Breast Cancer
Primary: Pathologic Complete Response (pCR) — 7; 1 Participants
Condylomata Acuminata · Papillomavirus Infections · Skin Diseases, Viral
Primary: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts at the Study Day 84 (End of Treatment) Visit. — 11; 1; 9; 0 Participants — p=0.0048
Primary Myelofibrosis · Secondary Myelofibrosis · Myeloid Malignancies
Primary: MF Participants: Percentage of Participants With Overall Response (OR) - (Clinical Improvement[CI] or Partial Remission[PR] or Complete Remission[CR]) Per International…
Colorectal Cancer
Primary: Objective Response Rate (ORR) During the Combination Therapy Phase — 29.2; 35.2; 46.3; 0 percentage of patients
Sepsis, Severe · Septic Shock
Primary: Time to Vasopressor Independence (Hours) — 27; 53 hours — p=<0.001
Lymphoma
Primary: Platelet (PLT) Nadir — 20.3; 26.3; 24.8; 22.5 K/μL